Bayer CropScience is currently trading at Rs. 4447.30, up by 5.55 points or 0.12% from its previous closing of Rs. 4441.75 on the BSE.
The scrip opened at Rs. 4521.55 and has touched a high and low of Rs. 4525.00 and Rs. 4444.70 respectively. So far 1889 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 6127.45 on 13-Aug-2021 and a 52 week low of Rs. 4101.20 on 24-Feb-2022.
Last one week high and low of the scrip stood at Rs. 4567.10 and Rs. 4284.95 respectively. The current market cap of the company is Rs. 20035.63 crore.
The promoters holding in the company stood at 71.43%, while Institutions and Non-Institutions held 15.52% and 13.05% respectively.
Bayer CropScience’s parent firm -- Bayer AG has signed a definitive agreement with global private equity firm Cinven to sell its environmental science professional business for $2.6 billion. The transaction is expected to close in the second half of this year, subject to the satisfaction of customary closing conditions. Its net proceeds are to be used to reduce Bayer's net financial debt.
This divestment represents a very attractive purchase price and allows the company to focus on its core agricultural business and the successful implementation of its Crop Science Division growth strategy.
Bayer CropScience is a world leader in the areas of crop protection pest control seeds and plant biotechnology. The company offers comprehensive solutions for modern sustainable agriculture and non-agricultural applications.
| Company Name | CMP |
|---|---|
| UPL | 665.00 |
| PI Industries | 3144.45 |
| Bayer CropScience | 4900.45 |
| Sharda Cropchem | 1109.70 |
| Sumitomo Chemical | 441.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: